CRP and lymphopenia: The data obtained from the present clinical trial demonstrated that berberine (300 mg, TID for 14 days) had no significant effect on clinical symptom improvement (cough, shortness of breath, nausea, loss of smell and taste, runny or stuffy nose, diarrhea, dizziness, sore throat, stomachache, body aches, and body temperature), quantitative CRP, lymphopenia, WBC, lymphocytes, neutrophils, platelets, and SpO2.